SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|
| OVITRELLE 250MCG-0.5ML PRE-FILLED SYRING | 0.5 mg/ml | Solution for injection/infusion · Intramuscular use | 1 Pre-filled syringe | SAR 146.37 | Biological · Prescription | SERONO | Valid |
| OVITRELLE 250MCG POWDER & SOLVENT FOR INJ | 250 µg | Solution for injection/infusion · Intramuscular use | 1 Vial | SAR 142.30 | Biological · Prescription | SERONO | Invalid · Not Marketed |
| PREGNYL +SOLVENT | 1500 IU | powder for solution for injection · Intramuscular use | 3 Ampoule | SAR 41.25 | Biological · Prescription | ORGANON | Withdrawn by MAH · Not Marketed |
| PREGNYL 5000 IU AMP+SOLVENT | 5000 IU | Solution for injection · Intramuscular use | 3 Ampoule | SAR 142.30 | Biological · Prescription | ORGANON | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|
| OVIDREL | EQ 0.25MG /0.5ML | injectable · subcutaneous | EMD SERONO | Prescription | 20 Sep 2000 |
| OVIDREL | 0.25MG/VIAL | injectable · injection | EMD SERONO | Discontinued | 20 Sep 2000 |
EMA European Union — centrally authorised medicines
Ovitrelle Merck Europe B.V. · Authorised · authorised 2 Feb 2001 · ATC G03GA08
Therapeutic indication (EMA)
Ovitrelle is indicated in the treatment of: women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (IVF): Ovitrelle is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth; anovulatory or oligo-ovulatory women: Ovitrelle is administered to trigger ovulation and luteinisation in anovulatory or oligo-ovulatory patients after stimulation of follicular growth.
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|
| OVIDREL | 02262088 | 250 MCG / 0.5 ML | SOLUTION · SUBCUTANEOUS | EMD SERONO, A DIVISION OF EMD INC., CANADA |
| OVIDREL | 02371588 | 250 MCG / 0.5 ML | SOLUTION · SUBCUTANEOUS | EMD SERONO, A DIVISION OF EMD INC., CANADA |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|
| US NADAC | OVIDREL 250 MCG/0.5 ML SYRG | $485.432 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Choriogonadotropin alfa 250micrograms/0.5ml solution for injection pre-filled syringes | £37.66 | 1 pre-filled disposable injection | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.